Related references
Note: Only part of the references are listed.BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial
Eric J. Lawitz et al.
HEPATOLOGY (2022)
Liquid biomarkers for fibrotic NASH - progress in a complex field
Detlef Schuppan et al.
JOURNAL OF HEPATOLOGY (2022)
ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway
Qi Liu et al.
CELL DEATH DISCOVERY (2022)
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri et al.
JOURNAL OF HEPATOLOGY (2022)
Emerging therapeutic opportunities for integrin inhibitors
R. J. Slack et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2021)
Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3β and suppression of Wnt/β-catenin pathway in hepatic stellate cells
Il Ho Lee et al.
PHYTOTHERAPY RESEARCH (2021)
Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
Kristina Duspara et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2021)
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Zoe Boyer-Diaz et al.
JOURNAL OF HEPATOLOGY (2021)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba et al.
HEPATOLOGY (2021)
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
V. Ratziu et al.
NATURE MEDICINE (2021)
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle et al.
NATURE MEDICINE (2021)
Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Georgios Kalopitas et al.
NUTRITION (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Stephen A. Harrison et al.
NATURE COMMUNICATIONS (2021)
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
Arun J. Sanyal et al.
JHEP REPORTS (2021)
Molecular and cellular mechanisms of liver fibrosis and its regression
Tatiana Kisseleva et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Rapid Intestinal Uptake and Targeted Delivery to the Liver Endothelium Using Orally Administered Silver Sulfide Quantum Dots
Nicholas J. Hunt et al.
ACS NANO (2020)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
Cristy R. C. Verzijl et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Mohammad Shadab Siddiqui et al.
JOURNAL OF HEPATOLOGY (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study
Arthur Bergman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Mesenchymal stem cell therapy for liver fibrosis/cirrhosis
Yan Cao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy
De Ji et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
Stephen A. Harrison et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting
Kim Huard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Hepatocyte cannabinoid 1 receptor nullification alleviates toxin-induced liver damage via NF-κB signaling
Yoo Kim et al.
CELL DEATH & DISEASE (2020)
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
Amos Baruch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage
Michal Segal-Salto et al.
JHEP REPORTS (2020)
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease
Adel Hammoutene et al.
JOURNAL OF HEPATOLOGY (2019)
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Hong-Wei Wu et al.
CLINICAL CANCER RESEARCH (2019)
New dual peroxisome proliferator activated receptor agonistSaroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Upendra Kaul et al.
CARDIOVASCULAR DIABETOLOGY (2019)
ECM1 Prevents Activation of Transforming Growth Factor β, Hepatic Stellate Cells, and Fibrogenesis in Mice
Weiguo Fan et al.
GASTROENTEROLOGY (2019)
An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis
Yanping Li et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Rohit A. Sinha et al.
THYROID (2019)
Sorafenib-Loaded Ligand-Functionalized Polymer-Lipid Hybrid Nanoparticles for Enhanced Therapeutic Effect Against Liver Cancer
Shijing Tang et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
Dual PPAR/agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Mukul R. Jain et al.
LIVER INTERNATIONAL (2018)
Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12
Busra Ozturk Akcora et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
Donghee Kim et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Jerry R. Colca et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
Insights into the Role of PPARβ/δ in NAFLD
Jiapeng Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
Joanne E. Murphy-Ullrich et al.
MATRIX BIOLOGY (2018)
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Detlef Schuppan et al.
MATRIX BIOLOGY (2018)
Cell type-specific pharmacological kinase inhibition for cancer chemoprevention
Manjeet Deshmukh et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Direct effects of thyroid hormones on hepatic lipid metabolism
Rohit A. Sinha et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Triggering and resolution of inflammation in NASH
Susanne Schuster et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis
Dhadhang Wahyu Kurniawan et al.
JOURNAL OF CONTROLLED RELEASE (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman et al.
GUT (2017)
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Johanne Poisson et al.
JOURNAL OF HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease A meta-analysis (PRISMA) of randomized control trials
Sheng Zhong et al.
MEDICINE (2017)
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
Chan Wah Kheong et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Hepatic stellate cells as key target in liver fibrosis
Takaaki Higashi et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
TGF-β signalling and liver disease
Isabel Fabregat et al.
FEBS JOURNAL (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials
Kai Qu et al.
FRONTIERS IN PHARMACOLOGY (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Eric Lefebvre et al.
PLOS ONE (2016)
FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Rotonya M. Carr et al.
CURRENT ATHEROSCLEROSIS REPORTS (2015)
Anti-inflammatory effect of resveratrol in old mice liver
Bui Thanh Tung et al.
EXPERIMENTAL GERONTOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model
Reju George Thomas et al.
PLOS ONE (2015)
Macrophage heterogeneity in liver injury and fibrosis
Frank Tacke et al.
JOURNAL OF HEPATOLOGY (2014)
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Bogna Grygiel-Gorniak
NUTRITION JOURNAL (2014)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Hedgehog signaling in the liver
Alessia Omenetti et al.
JOURNAL OF HEPATOLOGY (2011)
Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats
Marc Mejias et al.
HEPATOLOGY (2009)
Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases
Hitoshi Yoshiji et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice
L Yang et al.
JOURNAL OF HEPATOLOGY (2005)
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
S Yokohama et al.
HEPATOLOGY (2004)
Share Paper
